Clostridium Difficile

Animal-Assisted Visitation Program Chlorhexidine Trial

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Fecal Microbiome Transplant

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs

Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection

FQ Restriction for the Prevention of CDI

A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

Effects of Gastric Acid on Colonic Microbiome

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection

Immune Response to C.Difficile Infection

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

C Difficile Near-patient Diagnostics

Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea